the proximal colon segment were securely attached with string to an input and output port of the 128 saline, respectively. In order to monitor intraluminal pressure (cmH 2 O), a Mikro-Tip catheter 129 pressure transducer Millar Instruments, Houston, TX) was set in the lumen of the aboral 130 end. Motility was initiated by loading an intraluminal pressure to approximately 4 cmH 2 O by 131 elevating the drain tube. After an equilibration period of 120-240 min, contraction had reached a 132 consistent pattern, in terms of amplitude and frequency. The intraluminal pressure waves were 133 evaluated by a data acquisition and analysis system (MP100, BIOPAC System, Goleta, CA). The 134 motility was macroscopically observed through video images (PCR-SR87, SONY, Tokyo, Japan). 135
All drug solutions were added to Krebs solution in the organ bath (serosal side). Peak frequency (PF) 136
was calculated as the mean number of pressure peaks per minute during a defined period. The peak 137 pressure amplitude (PPA) was calculated as the mean pressure of peaks during an allotted time 138 period. The area under the curve (AUC) during the allotted time period was also calculated. 139
The %-PF, % -PPA and %-AUC of each period were calculated as the ratio to the PF, PPA and 140 AUC before drug treatment, respectively. 141
Spatiotemporal mapping 142
A "spatiotemporal map", which is an image representation of motor activity, was generated 143 according to the method described by Huisinga et al. (11) . Colon width (coded as image intensity, 144 black to white) is calculated at each point along the length of the colon (image Y-axis), for eachvideo frame (image X-axis) using ImageJ software. As shown in Figure 1C , propagating 146 contractions are represented as the diagonal streaks of dark color. Broad relaxation is represented as 147 white area. 148
RT-PCR 149
Muscle layer was carefully detached from the rat ascending colon and the remaining layer was used 150 as the mucosal layer. Total RNA was prepared with RNeasy Universal Tissue Kit (QIAGEN, 151 Hilden, Germany) and cDNA was synthesized with High Capacity cDNA Reverse Transcription 152
Kits (Life Technologies) according to the manufacturer's instructions. Sequences of sense and 153
anti-sense primers for RT-PCR analysis were as follows: rat KCNK3 sense: 154 5'-TCATCACCACAATCGGCTAT-3', anti-sense: 5'-AGCGCGTAGAACATGCAGAA-3', rat 155
KCNK9
sense: 5'-CCTTCTACTTCGCTATCAC-3', anti-sense: 156 5'-CCAGCGTCAGAGGGATAC-3', KCNK18 sense: 5'-CTCACTTCTTCCTCTTCTTCTC-3', 157 anti-sense:
5'-TAGCAAGGTAGCGAAACCTCT-3' and GAPDH sense: 158 5'-CGCATCTTCTTGTGCAGT-3', anti-sense: 5'-AATGAAGGGGTCGTTGATGG-3'. An aliquot 159 of the RT reaction product served as a template in 30 cycles with 10 s of denaturation at 98°C, 30 s 160 of annealing at 55°C, and 20 s of extension at 68°C using the DNA polymerase KOD FX 161 (TOYOBO, Osaka, Japan). A portion of the PCR mixture was electrophoresed through a 2% agarose 162 gel in Tris-acetate-EDTA buffer (pH 8.0), and the gel was stained with ethidium bromide and12 imaged on a Typhoon 9410 imager (GE Healthcare, Piscataway, NJ). 164
In situ hybridization 165
In situ hybridization (ISH) was performed by using QuantiGene ViewRNA. Gene specific probe sets 166 for rat KCNK3, KCNK9, PGP9.5 mRNAs were designed by Affymetrix (Santa Clara, CA). 167
Muscle layer was collected from rat ascending colon. Fixation and hybridization were conducted by 168 GeneticLab (Sapporo, Japan). Hybridized target mRNAs were visualized using bright-field 169 microscopy (BIOREV BZ-9000, Keyence, Osaka, Japan). 170
Immunohistochemistry 171
Whole mount immunohistochemistry was performed as follows: Intestinal specimens were opened 172 along the mesenteric border. The specimens were stretched taut and pinned out flat to a silicone ring 173 and fixed with ice cold acetone for 30 minutes. After fixation, each preparation was washed three 174 times for 10 minutes each in phosphate-buffered saline (PBS; 0.9% NaCl in 0.1 M sodium phosphate 175 buffer, pH 7.0). The preparations were placed in Superblock (Thermo Fischer Scientific, Rockford, 176 IL) containing 0.3% Triton X-100 overnight at 4°C. The preparations were then placed in primary 177 antibody diluted in antibody diluent (DAKO Japan, Tokyo, Japan) overnight at 4°C. After removal 178 from the primary antibody, the tissues were rinsed for 3 × 10 minutes with PBS and incubated with 179 the relevant secondary antibody conjugated to Alexa fluorochromes (Molecular Probes, Eugene, 180 OR) diluted in antibody diluent (DAKO Japan) overnight at 4°C. After a final set of rinses, thepreparations were mounted on microslides and coverslipped with Prolong Gold antifade reagent 182 (Molecular Probes). The slides prepared from whole mount or 7μm-thick sliced specimens were 183 observed using confocal laser microscopy FV-100D (Olympus, Tokyo, Japan). The following 184 antibodies were used: a mouse monoclonal antibody to KCNK9 (Sigma-Aldrich), a guinea pig 185 polyclonal antibody to PGP9.5 (Abcam plc, Cambridge, UK), rabbit polyclonal antibodies to 186 KCNK3 (Santa Cruz Biotechnology Inc. Dallas, TX), CD117 (DAKO Japan), platelet-derived 187 growth factor receptor (PDGFR)- (Santa Cruz Biotechnology) and smooth muscle actin and nuclei 188
were visualized by staining with Alexa568-conjugated phalloidin and 4',6-diamidino-2-phenylindole 189 (DAPI), respectively (Molecular Probes). In double immunostaining, each cell was identified by a 190 combination of DAPI and a respective marker, and double positive-and single positive-cells were 191 counted by visual inspection. 192
Preparation of plasmids and cRNAs 193
Rat KCNK3 cDNA was amplified from rat whole brain cDNA (Takara, Otsu, Japan) instructions. About 48hr after transfection, a membrane potential assay was performed using a 209 FLIPR Membrane Potential Assay Kit (Molecular Devices). The change of membrane potential was 210 monitored in terms of fluorescence intensity, measured using a FlexStation3 (Molecular Devices). 211
Analysis of defecation frequency 212
Normal Rats: HAS was orally administered and thereafter the rat's feces were counted 213 cumulatively during a 5 hr period under fasting. Laparotomy rats: Rats (7 -8 week old) were 214 incised about 4 cm in the median line of the abdomen after being anesthetized by intraperitoneal 215 injection of Somnopentyl (Kyoritsu Seiyaku, Tokyo, Japan). The small intestine, cecum and large 216 intestine were exteriorized and covered with sterile gauze dampened with saline for 1 hr beforereturning to the abdominal cavity and closing the abdomen. Rat feces were counted cumulatively 218 over a 7 hr period under the fasting state. Rats in the non-operation group were only anesthetized. 219 HAS and TU-100 were administered orally to rats by the gavage technique 3 or 4 hr after abdominal 220
closure. 221
Data analysis 222
All values are expressed as means ± SE. The statistical significance between 2 groups was evaluated 223
by F-test analysis of variance, followed by Student's t-test or Aspin-Welch's t-test. Statistical 224 significance between 3 or more groups was evaluated by Dunnett's test. When the agents were added 225 sequentially, repeated measure ANOVA was used. A probability of less than 0.05 was considered 226 statistically significant. 227
RESULTS

229
Evaluation of colonic motor activity by intraluminal pressure peaks and video imaging and 230
effect of HAS 231
Motility of isolated segments of the proximal colon was analyzed by the measurement of 232 intraluminal pressure and video image recordings. During a 2 hr period after the beginning of the 233 experiment, moderate amplitude pressure peaks were observed (see Figure 1A ). Thereafter the 234 amplitude of these pressure peaks weakened and by the 3 hr time point only very small peaks could 235 be detected (see Figure 1A , from time 3 hr to 4 hr). Nonetheless, low amplitude contractions were 236 still detected by video imaging, which appeared to be propulsive ( Figure 1A ; details shown in the 237 spatiotemporal map of Figure 1C ) until the end of the experiment. These types of contractions do not 238 always produce evident changes in pressure peaks. We performed quantitative analysis of colonic 239 motility mainly by assessing changes in the pressure because they are in good agreement with the 240 motility observed in video-imaging, at least for the high amplitude propagating motor activity. 241
Relationship between the intraluminal pressure chart and the video images is shown in 242
Supplementary Movie M1 and M2, and the relationship between the intraluminal pressure chart and 243 spatiotemporal map is shown in Figure 1C . It should be noted that for the low amplitude motor 244 activity, not all of the activity produces evident changes in the pressure peaks. Therefore, analyses 245 based on the pressure peaks may tend to underestimate its frequency.
As shown in Figure 1A , addition of HAS to the bath solution from the serosal side at 30 min and 3 247 hr induced high amplitude periodic pressure peaks with similar frequency and potency. The motility 248 is characterized by a strong squeezing over a broad range of the proximal colon ( Figures 1B, 1C , 249 movie files are shown in Supplementary Movie M3), after a brief temporal relaxation ( Figure 1C) . 250
The dose-dependency of pressure peak pattern, PF, PPA and AUC are shown in Figure 2 . 251
Contraction induced by HAS is not a result of stimulation of TRPV1/TRPA1 252
Firstly, we investigated whether TRPV1/TRPA1 agonists evoke motility similar to that induced by 253 HAS. A TRPV1 agonist capsaicin (0.1 -10 M) evoked a single contraction peak only, both at 30 254 min (data not shown) and 3 hr ( Figure 3A ) though its PPA was potent. A TRPA1 agonist 255 arylisothiocyanate (AITC) induced periodic contractions, although the amplitude was very small 256 even at high concentrations ( Figure 3B represents the result of AITC added at 100 M at 3 hr; 257
Supplementary Movie M5). Furthermore, administration of TRPV1 or TRPA1 inhibitor (BCTC and 258 HC-030031, respectively), and desensitization of TRPV1/TRPA1 by bolus application of high doses 259 of capsaicin plus AITC, gave no, or only a modest, suppression of colonic motility evoked by HAS 260 ( Figure 3C ). 261
Localization of KCNK9 and KCNK3 proteins 262
In order to investigate the possible involvement of these KCNK channels in HAS-induced motility, 263
RT-PCR was performed using specific primers for rat KCNK3, KCNK9 and KCNK18. Our resultsshow that KCNK3 and KCNK9 mRNAs are expressed in the muscle layer, whereas KCNK18 265 mRNA is barely detectable in the rat proximal colon ( Figure 4A ). The localization of KCNK3 and 266 KCNK9 was evaluated by ISH and immunohistochemistry. As shown in Figure 
HAS induced membrane depolarization via blocking rat KCNK9 282
It is not known whether HAS and HBS inhibit rat KCNK3 and/or KCNK9. Thus, we conducted two 283 electrode voltage clamp assays using Xenopus oocytes expressing rat KCNK3 or KCNK9. Because 284 both channels were reported to be regulated by extracellular pH, application of pH6.5 solution was 285 used as a positive control. Inhibitory effect of test compounds were determined with a holding 286 potential of +60 mV. LID was used as a non-selective KCNK channel blocker, which strongly 287 inhibited both KCNK3 and KCNK9. As shown in Figure 6A , HAS showed significant and dose 288 dependent inhibition against KCNK3 and KCNK9 while HBS inhibited only KCNK3. These results 289 were comparable to those observed for murine KCNKs (1). 290 KCNK channels regulate the excitability of cells such as smooth muscle and neurons by adjusting 291 their membrane potential. To address whether HAS inhibition against KCNK3 and KCNK9 led to 292 membrane depolarization, we examined the membrane potential of rat KCNK3-or 293 KCNK9-expressing CHO-K1 cells ( Figures 6B, 6C ) by using a membrane potential dye. In this 294 assay, the fluorescent signal increases during membrane depolarization and decreases during 295 membrane hyperpolarization. For example, the application of KCl increased the fluorescent signal, 296 which represents a depolarizing membrane potential. The KCl-induced changes in fluorescence 297 intensity for KCNK3 and KCNK9 expressing cells were larger than that observed for the mock cells 298 ( Figure 6B ). Data are represented by the normalized change in fluorescence (F/F 0 ). Inhibition of 299 KCNK3 or 9 was determined at 100 seconds after compound application. The application of HASand LID to KCNK3-and KCNK9-expressing cells significantly increased the fluorescence intensity. 301
The effect induced by 30 M of HAS was comparable to that induced by 1 mM of LID, although 302 LID induced depolarization not only in KCNKs-expressing cells but also in mock cells ( Figure 6C) . 303 HBS appeared to induce depolarization of KCNK3-expressing cells but the effect was not significant 304 ( Figures 6B, 6C) . 305
HBS and LID induce colonic motor patterns different from HAS 306
Although HAS, HBS, and LID raised the intraluminal pressure of rat isolated colons, and induced 307 potent contraction/motility, the resulting motor patterns differed among these three compounds. 308
While the pressure peaks induced by HAS were strong and repeated periodically with almost the 309 same frequency, those induced by HBS were lower in frequency and less periodic ( Figure 7A , 310
Supplementary Movie M6). The effects induced by LID were also weaker in amplitude, not periodic, 311 but higher in frequency than those induced by HAS ( Figure 7B , Supplementary Movie M7). The 312 spatiotemporal maps also suggested that HAS induces potent motor activity propagating from the 313 oral side to the aboral side over the entire proximal colon ( Figure 1A ), while LID was found to 314 induce high frequency, low amplitude, non-propulsive motor activity ( Figure 7B ). Table 1 shows the 315 PF of HAS-, HBS-, and LID-induced colonic motility. 316
High amplitude contraction by HAS is nerve-mediated. 317
The contractions induced by 10 M HAS were suppressed almost completely by addition of TTX(0.3 M), a neuroleptic agent ( Figure 8A ). By contrast, the contractions induced by HBS were not 319 abolished but its shape was changed by TTX ( Figure 8B ). Addition of high doses (up to 3 mM) of 320 TTX did not alter the effect of LID (1 mM, data not shown). 321
HAS accelerates defecation in normal and POI model rats. 322
In order to investigate whether HAS accelerates defecation in vivo we examined the amount of feces 323 accumulated during a short period after treatment with the agents. The accumulated number of fecal 324 pellets increased significantly at 5 hr after oral administration of 50 mg/kg HAS to normal rats 325 ( Figure 9A) . 326
For rats that had undergone abdominal surgery, the number of pellets decreased significantly 7 hr 327 after suturing ( Figure 9B ). Oral administration of HAS at 3 hr after the operation significantly 328 increased the number of pellets 4 hr after administration (i.e., 7 hr after the operation) in a 329 dose-dependent manner ( Figure 9C ). Accordingly, a single oral administration of TU-100 3 hr after 330 the operation also increased the number of pellets 3 hr after drug treatment (i.e., 6 hr after the 331 operation) in a dose-dependent manner. A significant outcome was obtained at a dose of 3 g/kg 332 TU-100 ( Figure 9D) . 333 334 DISCUSSION 336 HAS was found to induce high amplitude of contractions with significant levels of periodicity. The 337 peak frequency (~ 0.5/min), propagating/propulsive property, sensitivity to TTX and the presence of 338 relaxation phase preceding a very strong contractions are in good agreement with those reported for 339 LDC (11). LID, however, was found to induce low amplitude contractions with high frequency 340 (~6/min), which were non-propulsive and insensitive to TTX (i.e., in good agreement with RPR 341 (11)). The increase in amplitude induced by HBS might be periodic, but the interval between 342 consecutive peaks were wider and the incidence of the peaks appeared more irregular compared to 343 those induced by HAS. As shown in Figure 3 , "LDC" induced by HAS was not caused by the 344 agonistic activity of TRPV1/TRPA1, which is well documented for HAS and HBS. We reasoned 345 that the target molecules of HAS, HBS and LID may be KCNK channels because these agents, 346 especially HAS and HBS, have a high specificity for KCNK3 and/or KCNK9. Bautista et al (1) have 347 screened various ion channels including KCNK1~6, 9, 10, 13, 16 and 18 and reported specific 348 inhibition of KCNK3 by HBS and of KCNK3/9/18 by HAS. LID blocks a broad range of KCNKs. 349
Although many of the biological activities of LID can be attributed to its inhibitory activity against 350 multiple voltage-gated sodium channels, the effect on KCNK3 has been suggested to be involved in 351 LID-induced seizure in mice (6). 352 KCNK ion channels comprise a family of potassium-selective channels that share the uniquestructural feature of four transmembrane domains and two pore-forming domains (8). The KCNK 354
channel family are open across the physiological voltage range and are therefore believed to underlie 355 many of the background K + currents (also known as resting, baseline, or leak currents) that regulate 356 the resting membrane potential and excitability of many mammalian cells (2, 7, 21). KCNK channels 357 are found in neuronal and non-neuronal tissues, and they provide, in addition to setting of resting 358 membrane potentials (13, 23), a wide variety of important functions, including sensing of oxygen 359 and pH, neuroprotection, and mechanosensitivity (28). These channels are also candidates for the 360 action of volatile anaesthetics on neural excitability (27). Molecular analysis of GI smooth muscle 361 myocytes revealed expression of KCNK genes, including KCNK2, KCNK10 (14), KCNK3 and 362 KCNK5 (28), and the properties of the currents produced by these channels have been shown to 363 contribute to the native currents observed in GI smooth muscle (4). These data suggest that certain 364 KCNK family channels may be involved in the regulation of GI motility. 365 Interestingly, we found that the KCNK9/KCNK3 blocker HAS evokes a unique motor pattern with a 366 high-degree of periodicity while its geometric isomer, HBS, specifically blocked KCNK3 and 367 induced a motor pattern different from that of HAS. This observation suggests that the highly 368 periodic LDC evoked by HAS may be mediated by KCNK9. In the present study, we show that 369 KCNK3 is located in LM SMC and presumably a small portion of neuronal cells in MP, whereas 370 KCNK9 is located mainly in a portion of neuronal cells in MP and CM layer. These findings are ingood accordance with previous immunohistochemical studies using mouse (14, 28) and human (19) 372 GI tissue. The location of KCNK9 suggests that the channel may be involved in the determination of 373 resting potential and excitability of a substantial portion of enteric neurons innervating the MP and 374 CM layer. The "LDC" induced by HAS was completely abrogated by TTX treatment. If HAS blocks 375 KCNK9 in these motor neurons, their excitability will be augmented. Under such conditions, even if 376 signals with similar intensity are provided from upstream neurons (e.g., interneurons and intrinsic 377 primary afferent neurons) and/or enteroendocrine cells, the strength of the signals to the ICC/SMC 378 will differ substantially. Furthermore, while our data indicates that KCNK9 is not expressed in SMC, 379
it addressed the possibility of its expression in ICC in MP (ICC-MP). ICC-MP network is a 380
pacemaker and has been suggested to actively propagate rhythmic transient depolarizations 381 responsible for RPMC and/or LDC (11, 29) . If HAS affects ICC-MP to augment its functions, (i.e., 382 to generate more intense and well-regulated electrical periodicity), the agent would evoke potent and 383
regular "LDC" as demonstrated in the present results. 384
Because KCNK3 exists predominantly in LM SMC, it is thought to be involved in the regulation of 385 excitability of SMC, which may chiefly affect the tone of muscle contractility. The present study 386
indicates that KCNK3 might be expressed in some neurons in MP. This fiding is intriguing because 387 the effect of HBS, the blocker of KCN3, was not abrogated but its potency and frequency were 388 changed by TTX, suggesting a possible involvement of motility control system of both neurogenicand myogenic origin. Chen et al. (3) has demonstrated that myogenic mechanisms could be involved 390 in certain LDC-like rhythmic activity. Thus, further detailed examination is necessary to clarify the 391 effect of KCNK3 on colonic motility. 392
The properties of the LID-induced motility are in good accordance with those of RPR, which is 393 thought to be mediated by the submuscular ICC (ICC-SMP) network (11). LID is primarily a potent 394 inhibitor of several voltage-gated sodium channels and has a wide array of biological activities 395 including the effects on other KCNK family channels (5, 20) in which the blocking of KCNK3 is 396 only one item of the array. Accordingly, 1 mM LID significantly increased the membrane potential 397 in KCNK3-, KCNK9-and mock-transfected CHO-K1 cells, which strongly suggests that the 398 depolarization by LID may be due to a mechanism other than its inhibition of KCNK3/9. 399 HAS is a major ingredient of TU-100, which has been integrated into the modern medical system 400 under the approval of the Ministry of Health, Labor and Welfare of Japan. Basic research has 401 revealed the various beneficial effects of TU-100 on intestinal motility (9, 30, 32), adhesion (31), 402 vasodilatation (16), and inflammation (15). Clinical trials of TU-100 are currently underway in the 403 U.S. aimed at the development of novel therapeutic treatments for various intestinal disorders. These 404 studies include research on GI and colonic transit by validated scintigraphy, which has indicated 405 TU-100 significantly accelerates ascending colon empting in healthy human volunteers (22) . 406 Pharmacokinetics studies have shown that, when TU-100 is administered orally, HAS is rapidlyabsorbed in the gut and reaches high concentrations in the blood (approximately 1 M in human and 408 rats) within 15 min (12, 24, 25) . The present experimental settings for the bath application of HAS to 409 the proximal colon is in reasonable agreement with the clinical situation of orally-administered 410 TU-100 in terms of the pharmacological and pharmacokinetic properties of the drug. Furthermore, 411
we have observed that low dosages of HAS, which are too low to induce "LDC" alone, enhance 412 motility triggered by other stimuli such as bethanechol, capsaicin or gingerol (data not shown). This 413 observation is in good accordance with the assumed mechanism of action of HAS, i.e., augmentation 414 of excitability of enteric motor neurons via blocking KCNK9. 415
In order to investigate whether the induction/enhancement of "LDC" in vitro relates to the colonic 416 transit in vivo, we have examined the effect of HAS or TU-100 on defecation of normal and 417 postoperative rats. A single administration of HAS or TU-100 increased the number of fecal pellets 418 accumulated over a short period of time (3-4 hr after drug treatment and 6-7 hr after surgery). 419
Although the present study may provide potentially interesting findings, there are several points to 420 be validated and investigated in future studies. Firstly, involvement of KCNK channels in 421 HAS/HBS/LID-mediated motility is still unclear. The use of more specific agonists and/or 422 antagonists, and gene-manipulated mice is necessary to clarify this point. Secondly, further 423 investigation into the biological function of KCNK channels in the generation of slow wave activity, 424 rhythmic transient depolarizations and colonic motility is needed. In the present study, we have27 demonstrated that KCNK channels strongly affect the membrane potential in the cell line. However, 426 detailed analyses on gastrointestinal cells and tissues, such as the measurement of inhibitory junction 427 potential, have yet to be performed. Thirdly, whether the KCNK9 channel is expressed in ICC-MP 428 should be determined by more conclusive and quantitative methods such as more extensive 429 morphometrical immunohistochemistry of the tissues and analysis of KCNK9 protein and mRNA in 430 purified ICCs. If KCNK9 is expressed in a subpopulation of ICC-MP, it will be reasonable for HAS 431 to modulate the pace-making of colonic motility. Elucidation of these points will undoubtedly 432 contribute to a deeper understanding of the physiology and molecular biology of colonic motor 433
activities. 434
In conclusion, we have demonstrated that HAS may induce or enhance "LDC" of the proximal colon 435 presumably elevating the excitability of enteric nerves via KCNK9 blocking. The present findings 436 provide not only a clarification of the mechanism of action of a promising new medicine TU-100, 437 but also a way to develop a novel therapeutic strategy for the treatment of intestinal dysmotility. contractility. %-PF, %-PPA and %-AUC are shown (n = 4 -6). *P < .05, **P < .01, ***P < .001 vs. 559
Vehicle control. 560 HAS (n = 6) and 30 M HBS (n = 5 and 6) were used. *P < .05, **P < .01 vs. Control (vehicle). 594 Figure 9 . The acceleration of defecation by HAS and TU-100 in normal rats or POI model rats. A. 595
The increase of defecation frequency at 5 hr after HAS (50 mg/kg p.o.) administration in normal rats. 596 *P < .05, **P < .01 vs Vehicle (olive oil 0.5 mL/kg p.o.) (n=8). B. The decrease of defecation 597 frequency by laparotomy. *P < .05, ***P < .001 vs Normal (anesthetized only). (n = 8 ~21, at 7 hrs 598 after operation). C. The increase of defecation frequency after HAS (15 and 50 mg/kg p.o.) dosing at 599 4 hrs after administration (i.e., 6 hrs after operation) in POI rats. * P < .05 vs Vehicle (n = 23-25). D. 600
The acceleration of defecation frequency induced TU-100 (1 and 3 g/kg p.o.) dosing 3 hrs after 601 administration (i.e., 6 hrs after operation) in POI rats. *, ** P < .05, .01 vs Vehicle (water 15 mL/kg 602 p.o.) (n = 8 or 9). 603 The number of peaks during a set period of time was counted in the pressure peak chart and peak 607 frequency (PF) was calculated as the number of peaks per minute. N = 4 -7. 608 609
